Machine Learning

A novel CRISPR-based therapy safely targets deadly E. coli in the gut, showing promise in the fight against antibiotic resistance and for protecting cancer patients.

With a pivotal trial for pancreatic cancer looming, Immuneering will detail its novel 'Deep Cyclic Inhibitor' platform and strategy to investors.

With soaring revenue and new EU approval, Senseonics is taking control of its sales, but rising costs raise questions about its path to profitability.

Entrepreneur Daniel Gestetner discusses resilience, a $1B exit, and why true success isn't about winning at all costs in a revealing new podcast.

Team Velocity's new AI assistant is moving beyond chatbots, enabling real-time transactions on dealer sites and delivering major boosts in lead generation.

At MWC, Lifecycle Software unveils NEXUS® IQ, an AI platform promising to cut telco churn by 40% and transform raw customer data into profit.

Consark.ai's new Noa platform uses autonomous agents to execute complex accounting, promising a shift from human preparation to AI-led execution.

At MWC26, Huawei Cloud launched its Industry AI Foundry, a new hybrid cloud, and an AI coding agent, doubling down on AI to solve real-world problems.

A potential first-in-class therapy for two untreatable neurological diseases, co-discovered by AI and robotics, has begun human testing in a major milestone.

HTC's VIVERSE launches a global art contest, leveraging web technology to let anyone create and view immersive 3D art without needing a VR headset.

A promising oral therapy for Huntington's disease has been deemed eligible for accelerated review in Australia, offering new hope for a breakthrough.

An Israeli startup claims its 'Artificial Expert Intelligence' autonomously achieved a 3.6x speedup over a decade of human-engineered NVIDIA code.

A new board certification in Disaster Medicine will equip physicians across 14 specialties to lead during crises, enhancing healthcare system resilience.

A new AI-powered platform from industry veterans promises to transform P&C insurance, offering smaller carriers the tools to compete with giants.

A next-gen drug for chronic hives shows superior, faster results than the long-standing standard of care, heralding a potential shift in allergy treatment.

MARSOC veterans secure $32M for Smack Technologies, an AI lab building a 'Decision Dominance' platform designed to reshape U.S. military strategy.

As SAB Biotherapeutics prepares for key investor talks, a closer look reveals its novel T1D therapy and the unique bovine tech aiming to change treatment.

A new study aims to confirm a novel immunotherapy's dramatic results in colorectal cancer, offering hope for patients with limited treatment options.

Amorepacific's research-backed brand IOPE arrives at Sephora, challenging the US anti-aging market with patented technology and accessible pricing.

Halia Therapeutics is betting on a novel target to fight chronic inflammation. At a key summit, it will pitch its unique approach for cancer, obesity, and Alzheimer's.